GB0306615D0 - New use - Google Patents

New use

Info

Publication number
GB0306615D0
GB0306615D0 GBGB0306615.6A GB0306615A GB0306615D0 GB 0306615 D0 GB0306615 D0 GB 0306615D0 GB 0306615 A GB0306615 A GB 0306615A GB 0306615 D0 GB0306615 D0 GB 0306615D0
Authority
GB
United Kingdom
Prior art keywords
new use
lipoprotein
triglyceride
lipid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0306615.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0306615.6A priority Critical patent/GB0306615D0/en
Publication of GB0306615D0 publication Critical patent/GB0306615D0/en
Priority to CA002517191A priority patent/CA2517191A1/en
Priority to AU2004222409A priority patent/AU2004222409B2/en
Priority to NZ542505A priority patent/NZ542505A/en
Priority to PCT/SE2004/000417 priority patent/WO2004082702A1/en
Priority to BRPI0408522-1A priority patent/BRPI0408522A/pt
Priority to AT04722129T priority patent/ATE475417T1/de
Priority to EP04722129A priority patent/EP1608311B1/en
Priority to KR1020057017258A priority patent/KR20050114237A/ko
Priority to HK06104683.8A priority patent/HK1084329B/en
Priority to DE602004028348T priority patent/DE602004028348D1/de
Priority to CNA2004800072860A priority patent/CN1761479A/zh
Priority to ES04722129T priority patent/ES2346969T3/es
Priority to JP2006507972A priority patent/JP2006520813A/ja
Priority to US10/550,154 priority patent/US20060183692A1/en
Priority to MXPA05010159A priority patent/MXPA05010159A/es
Priority to NO20054285A priority patent/NO20054285L/no
Priority to ZA200507614A priority patent/ZA200507614B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pyrrole Compounds (AREA)
GBGB0306615.6A 2003-03-22 2003-03-22 New use Ceased GB0306615D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0306615.6A GB0306615D0 (en) 2003-03-22 2003-03-22 New use
MXPA05010159A MXPA05010159A (es) 2003-03-22 2004-03-19 Uso de inhibidores de trombina de bajo peso molecular, en terapia para disminuir el colesterol.
KR1020057017258A KR20050114237A (ko) 2003-03-22 2004-03-19 콜레스테롤-하강 치료시 저분자량 트롬빈의 용도
DE602004028348T DE602004028348D1 (de) 2003-03-22 2004-03-19 Verwendung von niedermolekularen thrombin-hemmern in der cholesterinsenkenden therapie
NZ542505A NZ542505A (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
PCT/SE2004/000417 WO2004082702A1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
BRPI0408522-1A BRPI0408522A (pt) 2003-03-22 2004-03-19 uso de um inibidor de trombina de baixo peso molecular ou de um seu derivado farmaceuticamente aceitável, métodos de terapia de redução de colesterol e de tratamento de hipercolestrolemia, hiperlipoproteinemia e/ou hipertrigliceridemia, produto combinado, e, formulação farmacêutica para uso na terapia de redução de colesterol
AT04722129T ATE475417T1 (de) 2003-03-22 2004-03-19 Verwendung von niedermolekularen thrombin-hemmern in der cholesterinsenkenden therapie
EP04722129A EP1608311B1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
CA002517191A CA2517191A1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
HK06104683.8A HK1084329B (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
AU2004222409A AU2004222409B2 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
CNA2004800072860A CN1761479A (zh) 2003-03-22 2004-03-19 低分子量凝血酶抑制剂在降低胆固醇治疗中的应用
ES04722129T ES2346969T3 (es) 2003-03-22 2004-03-19 Uso de inhibidores de trombina de bajo peso molecular en terapia de disminucion de colesterol.
JP2006507972A JP2006520813A (ja) 2003-03-22 2004-03-19 低分子量トロンビン阻害剤のコレステロール低下療法における使用
US10/550,154 US20060183692A1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
NO20054285A NO20054285L (no) 2003-03-22 2005-09-16 Anvendelse av trombin inhibitorer med lav molekylvekt i kolesterol-reduserede terapi
ZA200507614A ZA200507614B (en) 2003-03-22 2005-09-20 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0306615.6A GB0306615D0 (en) 2003-03-22 2003-03-22 New use

Publications (1)

Publication Number Publication Date
GB0306615D0 true GB0306615D0 (en) 2003-04-30

Family

ID=9955311

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0306615.6A Ceased GB0306615D0 (en) 2003-03-22 2003-03-22 New use

Country Status (17)

Country Link
US (1) US20060183692A1 (https=)
EP (1) EP1608311B1 (https=)
JP (1) JP2006520813A (https=)
KR (1) KR20050114237A (https=)
CN (1) CN1761479A (https=)
AT (1) ATE475417T1 (https=)
AU (1) AU2004222409B2 (https=)
BR (1) BRPI0408522A (https=)
CA (1) CA2517191A1 (https=)
DE (1) DE602004028348D1 (https=)
ES (1) ES2346969T3 (https=)
GB (1) GB0306615D0 (https=)
MX (1) MXPA05010159A (https=)
NO (1) NO20054285L (https=)
NZ (1) NZ542505A (https=)
WO (1) WO2004082702A1 (https=)
ZA (1) ZA200507614B (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237518B (it) * 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
AU2004222409A1 (en) 2004-09-30
CA2517191A1 (en) 2004-09-30
MXPA05010159A (es) 2005-11-16
HK1084329A1 (en) 2006-07-28
EP1608311A1 (en) 2005-12-28
JP2006520813A (ja) 2006-09-14
ZA200507614B (en) 2006-06-28
NO20054285L (no) 2005-10-20
CN1761479A (zh) 2006-04-19
NO20054285D0 (no) 2005-09-16
KR20050114237A (ko) 2005-12-05
BRPI0408522A (pt) 2006-03-07
EP1608311B1 (en) 2010-07-28
DE602004028348D1 (de) 2010-09-09
US20060183692A1 (en) 2006-08-17
ES2346969T3 (es) 2010-10-22
NZ542505A (en) 2009-01-31
ATE475417T1 (de) 2010-08-15
WO2004082702A8 (en) 2005-03-24
WO2004082702A1 (en) 2004-09-30
AU2004222409B2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2002028379A3 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
UA88265C2 (ru) Применение ингибитора ренин-ангиотензиновой системы для профилактики диабета
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
WO2007131168A3 (en) Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
WO2005005453A3 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
WO2002102981A3 (en) SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
WO2006089340A3 (en) Polynucleotide delivery to cardiac tissue
WO2003099281A3 (en) Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
ZA200608407B (en) Method and composition for treating rhinitis
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
WO2005016249A3 (en) Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
IL143824A0 (en) New dialysis method
WO2006051549A3 (en) Combination therapy associating preferably a ceramide with a cytotoxic drug
NO20055474L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
WO2001052855A8 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
WO2001078727A8 (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
GB0306615D0 (en) New use
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
WO1999009967A3 (en) Cholesterol-lowering therapy
AU2001259596A1 (en) Method and apparatus for the administration of continuous positive airway pressure therapy
AU2003225244A1 (en) Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels
AU2001243614A1 (en) Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
AU2003257814A1 (en) Medicinal composition for lowering blood lipid level
WO2004024094A3 (en) Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)